These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9525650)

  • 21. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2).
    Cayabyab M; Karlsson GB; Etemad-Moghadam BA; Hofmann W; Steenbeke T; Halloran M; Fanton JW; Axthelm MK; Letvin NL; Sodroski JG
    J Virol; 1999 Feb; 73(2):976-84. PubMed ID: 9882298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.
    Montefiori DC; Reimann KA; Wyand MS; Manson K; Lewis MG; Collman RG; Sodroski JG; Bolognesi DP; Letvin NL
    J Virol; 1998 Apr; 72(4):3427-31. PubMed ID: 9525675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
    Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
    Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
    J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.
    Laird ME; Igarashi T; Martin MA; Desrosiers RC
    J Virol; 2008 Nov; 82(22):11054-65. PubMed ID: 18768967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.
    Xu W; Hofmann-Lehmann R; McClure HM; Ruprecht RM
    Vaccine; 2002 May; 20(15):1956-60. PubMed ID: 11983253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
    Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
    AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SOSIP Trimer-Specific Antibodies Isolated from a Simian-Human Immunodeficiency Virus-Infected Monkey with versus without a Pre-blocking Step with gp41.
    Duggan NN; Weisgrau KL; Magnani DM; Rakasz EG; Desrosiers RC; Martinez-Navio JM
    J Virol; 2022 Jan; 96(2):e0158221. PubMed ID: 34730398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic and biological alteration of a human immunodeficiency virus type 1 (HIV-1)-simian immunodeficiency virus strain mac chimera, with HIV-1 Env, recovered from a long-term carrier monkey.
    Igarashi T; Kuwata T; Takehisa J; Ibuki K; Shibata R; Mukai R; Komatsu T; Adachi A; Ido E; Hayami M
    J Gen Virol; 1996 Aug; 77 ( Pt 8)():1649-58. PubMed ID: 8760411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
    Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM
    AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.
    Kitabwalla M; Ferrantelli F; Wang T; Chalmers A; Katinger H; Stiegler G; Cavacini LA; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 2003 Feb; 19(2):125-31. PubMed ID: 12639248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    Trkola A; Pomales AB; Yuan H; Korber B; Maddon PJ; Allaway GP; Katinger H; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Nov; 69(11):6609-17. PubMed ID: 7474069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
    Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
    J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission?
    Hofmann-Lehmann R; Rasmussen RA; Vlasak J; Smith BA; Baba TW; Liska V; Montefiori DC; McClure HM; Anderson DC; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Katinger H; Stiegler G; Posner MR; Cavacini LA; Chou TC; Ruprecht RM
    J Med Primatol; 2001 Aug; 30(4):190-6. PubMed ID: 11555137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120.
    Tilley SA; Honnen WJ; Racho ME; Chou TC; Pinter A
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):461-7. PubMed ID: 1376135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
    J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent infection of macaques with simian-human immunodeficiency viruses.
    Li JT; Halloran M; Lord CI; Watson A; Ranchalis J; Fung M; Letvin NL; Sodroski JG
    J Virol; 1995 Nov; 69(11):7061-7. PubMed ID: 7474126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.